Phase 2 Study of BL1107 Eye Drops vs. Timolol in Adults With Primary Open Angle Glaucoma or Ocular Hypertension
A Phase 2 Evaluation of the Safety, Ocular Tolerability, and Efficacy of Topical Ophthalmic BL1107 Versus Timolol in Adults With Primary Open Angle Glaucoma or Ocular Hypertension
1 other identifier
interventional
252
1 country
14
Brief Summary
Phase 2 Study of BL1107 Eye Drops vs. Timolol in Adults with Primary Open Angle Glaucoma or Ocular Hypertension
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for phase_2
Started Oct 2025
Shorter than P25 for phase_2
14 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
September 5, 2025
CompletedFirst Posted
Study publicly available on registry
September 11, 2025
CompletedStudy Start
First participant enrolled
October 24, 2025
CompletedPrimary Completion
Last participant's last visit for primary outcome
May 18, 2026
CompletedStudy Completion
Last participant's last visit for all outcomes
May 18, 2026
CompletedJuly 22, 2026
July 1, 2026
7 months
September 5, 2025
July 21, 2026
Conditions
Outcome Measures
Primary Outcomes (1)
Change from baseline in visual field mean deviation in the study eye at Day 28/Exit.
Assessed at Day 28
Secondary Outcomes (3)
Proportion of participants achieving ≥15-letter improvement in low-luminance best-corrected visual acuity (LL-BCVA) in the study eye at Day 28/Exit.
Assessed at Day 28
Proportion of participants achieving ≥10-letter improvement in low-luminance best-corrected visual acuity (LL-BCVA) in the study eye at Day 28/Exit.
Assessed at Day 28
Hour-matched change from Baseline in intraocular pressure (IOP) in the study eye at Day 28/Exit.
Assessed at Day 28
Study Arms (3)
BL1107 Low dose
EXPERIMENTALBL1107 High dose
EXPERIMENTALTimolol maleate 0.5%
ACTIVE COMPARATORInterventions
Eligibility Criteria
You may qualify if:
- Ocular hypertension or primary open-angle glaucoma in each eye
You may not qualify if:
- History of orthostatic hypotension
- Any active ocular disease
- Anticipated wearing of contact lenses during study
- Contraindication to pupil dilation
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (14)
Global Research Management, Inc.
Glendale, California, 91204, United States
Eye Research Foundation
Newport Beach, California, 92663, United States
California Eye Specialist Medical Group, LLC
Pasadena, California, 91107, United States
Eye Associates of Fort Myers
Fort Myers, Florida, 33901, United States
Levenson Eye Associates
Jacksonville, Florida, 32204, United States
Central Florida Eye Associates
Lakeland, Florida, 33805, United States
Lee Shettle Eye and Hearing
Largo, Florida, 33773, United States
Clayton Eye Clinical Research, LLC
Morrow, Georgia, 30260, United States
Coastal Research Associates, LLC
Roswell, Georgia, 30076, United States
Heart of America Eye Care
Shawnee Mission, Kansas, 66204, United States
Andover Eye Associates
Andover, Massachusetts, 01810, United States
Scott & Christie and Associates, PC
Cranberry Township, Pennsylvania, 16066, United States
Total Eye Care, P.A.
Memphis, Tennessee, 38119, United States
Houston Eye Associates
Houston, Texas, 77025, United States
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Design
- Study Type
- interventional
- Phase
- phase 2
- Allocation
- RANDOMIZED
- Masking
- DOUBLE
- Who Masked
- PARTICIPANT, INVESTIGATOR
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
September 5, 2025
First Posted
September 11, 2025
Study Start
October 24, 2025
Primary Completion
May 18, 2026
Study Completion
May 18, 2026
Last Updated
July 22, 2026
Record last verified: 2026-07